BLACKMORES LIMITED (BKL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

BKL - BLACKMORES LIMITED

FNArena Sector : Health & Nutrition
Year End: June
GICS Industry Group : Household & Personal Products
Index: ASX200 | ASX300 | ALL-ORDS

Blackmores is Australia's leading natural health supplement company manufacturing and marketing a range of food supplements, including vitamins, mineral and herb products. Founded in 1932, it became a public company in 1985.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$98.14

19 Oct
2021

-1.020

OPEN

$97.12

-1.03%

HIGH

$99.44

38,410

LOW

$97.12

TARGET
$86.30 -12.1% downside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
EBO . MCP . API . EXL . SIG . CLV .
FNARENA'S MARKET CONSENSUS FORECASTS
BKL: 1
Title FY20
Actual		 FY21
Actual		 FY22
Forecast		 FY23
Forecast
EPS (cps) xxx 128.5 217.2 xxx
DPS (cps) xxx 71.0 109.4 xxx
EPS Growth xxx 24.1% 69.1% xxx
DPS Growth xxx N/A 54.1% xxx
PE Ratio xxx N/A 47.1 xxx
Dividend Yield xxx N/A 1.1% xxx
Div Pay Ratio(%) xxx 55.3% 50.4% xxx

Dividend yield today if purchased 3 years ago: 0.58%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.69

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 08/09 - ex-div 42c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
Title 201620172018201920202021
EPS Basic xxxxxxxxxxxxxxx128.5
DPS All xxxxxxxxxxxxxxx71.0
Sales/Revenue xxxxxxxxxxxxxxx575.9 M
Book Value Per Share xxxxxxxxxxxxxxx1,926.9
Net Operating Cash Flow xxxxxxxxxxxxxxx58.7 M
Net Profit Margin xxxxxxxxxxxxxxx4.16 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201620172018201920202021
Return on Capital Employed xxxxxxxxxxxxxxx7.07 %
Return on Invested Capital xxxxxxxxxxxxxxx5.95 %
Return on Assets xxxxxxxxxxxxxxx4.27 %
Return on Equity xxxxxxxxxxxxxxx7.07 %
Return on Total Capital xxxxxxxxxxxxxxx11.64 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx43.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Credit Suisse

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

31/08/2021

3

Hold

$95.00

-3.20%

The FY21 result was materially weaker than Morgans expected, despite strong growth, particularly from China and the International businesses. For this country/segment, management remains positive on the outlook, with sales momentum continuing into FY22.

While A&NZ had a challenging year, (due to the loss of the daigou, a mild cold and flu season and reduced foot traffic in the pharmacy channel), the analyst was pleased by a rise in the gross profit (GP) and earnings (EBIT) margin.

After upgrading medium-to-longer-term forecasts, the broker lifts its target price to $95 from $86 and retains its Hold rating. By FY24, management hopes to increase the GP margin to the high 50% level and the earnings margin to around 15% versus 8.3% in FY21.

FORECAST
Morgans forecasts a full year FY22 dividend of 85.00 cents and EPS of 189.00 cents.
Morgans forecasts a full year FY23 dividend of 124.00 cents and EPS of 274.00 cents.

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

5

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

BKL STOCK CHART

FNArena News on BKL

1
Rudi’s View: BHP, Codan, Macquarie, Santos And QBE

Oct 14 2021 - Rudi's View
2
Rudi’s View: Telstra, Iress, NextDC And That Grand Delusion

Sep 23 2021 - Rudi's View
3
August In Review: Eleventh Month Of Gains

Sep 10 2021 - Australia
4
Weekly Ratings, Targets, Forecast Changes – 27-08-21

Aug 30 2021 - Weekly Reports
5
FNArena Corporate Results Monitor – 27-08-2021

Aug 27 2021 - Australia

Latest Health & Nutrition News

1
Health & Wellness Boom On The ASX

Apr 29 2021 - Weekly Reports
2
M&A Now On Sigma Healthcare’s Agenda

Mar 24 2021 - Australia
3
McPherson’s Expands Into Herbal Health

Nov 04 2020 - Small Caps
4
Nine Ignored Companies Now Worth A Look

Sep 23 2020 - FYI
5
Next Week At A Glance – 14-18 Sep 2020

Sep 11 2020 - Weekly Reports
6
Sigma Farewells API, Heralds New Contract

Dec 17 2019 - Australia
7
Blackmores: Hopes Pinned On Restructuring

Nov 01 2019 - Australia
8
Blackmores Peps Up Its Strategy For China

Apr 17 2019 - Australia
9
API/Sigma Merger Plan Rears, Again

Dec 17 2018 - Australia
10
Uncertainty Hinders Sigma Pharmaceuticals

Sep 11 2018 - Small Caps